Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19352098 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | October 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19208792 | ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER | May 2025 | October 2025 | Allow | 5 | 1 | 1 | No | No |
| 19193595 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING | April 2025 | March 2026 | Allow | 10 | 2 | 0 | No | No |
| 19193629 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING | April 2025 | October 2025 | Allow | 5 | 2 | 0 | No | No |
| 19193652 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19071424 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | March 2025 | August 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19050008 | NK/MONOCYTE ENGAGERS | February 2025 | July 2025 | Allow | 6 | 2 | 1 | No | No |
| 18939460 | METHODS COMPRISING ONCOLYTIC VIRUSES EXPRESSING CD19T AND BISPECIFIC T CELL ENGAGERS | November 2024 | February 2026 | Allow | 15 | 1 | 1 | Yes | No |
| 18829057 | METHOD OF REDUCING BISPECIFIC T CELL ENGAGER OR CHIMERIC ANTIGEN RECEPTOR T CELL MEDIATED CYTOKINE RELEASE SYNDROME USING INTERLEUKINS-4, -10, OR A FUSION PROTEIN THEREOF | September 2024 | December 2025 | Allow | 15 | 1 | 1 | No | No |
| 18731180 | CELL SIGNALING COMPLEXES AND USES THEREOF | May 2024 | December 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18651979 | ANTI-AGING SALMON ROE TRIPEPTIDE AND PREPARATION METHOD AND APPLICATION THEREOF | May 2024 | February 2025 | Allow | 10 | 2 | 0 | No | No |
| 18690247 | ANTI-PD-1 IMMUNOGLOBULIN POLYPEPTIDES AND USES THEREOF | March 2024 | May 2025 | Allow | 14 | 0 | 1 | No | No |
| 18501884 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | November 2023 | February 2024 | Allow | 4 | 0 | 0 | No | No |
| 18501914 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | November 2023 | May 2024 | Allow | 7 | 1 | 0 | No | No |
| 18501856 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | November 2023 | February 2024 | Allow | 3 | 0 | 0 | No | No |
| 18501584 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | November 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18501762 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | November 2023 | December 2023 | Allow | 2 | 0 | 0 | No | No |
| 18501850 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | November 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18501581 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | November 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18501561 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | November 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18501571 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | November 2023 | August 2024 | Allow | 9 | 2 | 0 | No | No |
| 18345885 | CELLS HAVING SOLID TUMOR TARGETING BACKBONE AND USE THEREOF | June 2023 | September 2024 | Allow | 14 | 1 | 1 | No | No |
| 18327127 | ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS | June 2023 | December 2023 | Allow | 7 | 2 | 0 | No | No |
| 17915109 | MONOCLONAL ANTIBODY BINDING TO TIGIT ANTIGEN, PREPARATION METHOD AND USE THEREOF | March 2023 | September 2023 | Allow | 12 | 1 | 0 | No | No |
| 18042158 | Methods and Compositions for Diabetes Treatment and Beta-Cell Regeneration | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18016352 | ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF | January 2023 | December 2025 | Allow | 35 | 1 | 0 | No | No |
| 18085632 | MULTI SUBUNIT PROTEIN MODULES, CELLS EXPRESSING SAME AND USES THEREOF | December 2022 | March 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18056681 | ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof | November 2022 | February 2026 | Allow | 39 | 1 | 0 | No | No |
| 18052110 | ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF | November 2022 | January 2026 | Allow | 38 | 2 | 0 | No | No |
| 18052076 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING | November 2022 | May 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18052099 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING | November 2022 | September 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18051773 | TARGETED BINDING AGENTS AGAINST B7-H1 | November 2022 | March 2026 | Allow | 40 | 0 | 1 | No | No |
| 17959065 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | October 2022 | September 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17936062 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | September 2022 | September 2025 | Allow | 36 | 1 | 1 | No | No |
| 17932822 | ANTI-CD26 ANTIBODIES AND USES THEREOF | September 2022 | November 2025 | Allow | 38 | 1 | 0 | No | No |
| 17822251 | CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | August 2022 | January 2023 | Allow | 5 | 0 | 0 | No | No |
| 17822054 | COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY | August 2022 | June 2025 | Allow | 34 | 1 | 0 | No | No |
| 17878667 | PD-1 Binding Proteins and Methods of Use Thereof | August 2022 | September 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17796661 | ANTIBODY, RELATED USE, PHARMACEUTICAL COMPOSITION INCLUDING METHOD FOR DIAGNOSING FUNGAL INFECTIONS, FUNGAL INFECTION DIAGNOSIS KIT AND METHOD FOR TREATING FUNGAL INFECTIONS | July 2022 | December 2025 | Allow | 40 | 1 | 0 | No | No |
| 17870479 | ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS | July 2022 | July 2023 | Allow | 12 | 1 | 1 | No | No |
| 17811489 | REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF | July 2022 | September 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17842540 | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1) | June 2022 | March 2026 | Abandon | 45 | 1 | 1 | No | No |
| 17806187 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | June 2022 | July 2025 | Allow | 37 | 1 | 0 | No | No |
| 17835936 | FUSION PROTEINS OF PD-1 AND 4-1BB | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17831637 | CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF | June 2022 | August 2025 | Allow | 39 | 1 | 0 | No | No |
| 17828513 | GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF | May 2022 | January 2026 | Allow | 43 | 1 | 1 | No | No |
| 17825297 | MICROVASCULAR BLOOD FLOW DECREASING AGENT AND USE THEREOF | May 2022 | May 2025 | Allow | 36 | 1 | 0 | No | No |
| 17750658 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof | May 2022 | December 2022 | Allow | 7 | 1 | 0 | No | No |
| 17664589 | FLT3 LIGAND FUSION PROTEINS AND METHODS OF USE | May 2022 | August 2022 | Allow | 3 | 0 | 0 | No | No |
| 17776201 | TREATMENT OF FIBROSIS WITH COMBINED BLOCKADE OF IL-6 AND IMMUNE CHECKPOINT | May 2022 | February 2026 | Allow | 45 | 1 | 0 | No | No |
| 17662518 | ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF | May 2022 | August 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17662606 | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND METHODS OF USE THEREOF | May 2022 | June 2025 | Allow | 37 | 0 | 0 | No | No |
| 17736917 | NOVEL CTLA4-IG IMMUNOADHESINS | May 2022 | August 2025 | Allow | 39 | 1 | 0 | No | No |
| 17772631 | Methods of Treating Cancer with Anti-PD-1 Antibodies | April 2022 | February 2026 | Abandon | 46 | 1 | 0 | No | No |
| 17725199 | ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF | April 2022 | June 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17285184 | ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME | April 2022 | February 2026 | Allow | 58 | 1 | 1 | No | No |
| 17721647 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17288187 | ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof | March 2022 | September 2022 | Allow | 16 | 1 | 0 | No | No |
| 17760738 | ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOF | March 2022 | December 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17685056 | B7-H4 ANTIBODIES AND METHODS OF USE THEREOF | March 2022 | March 2026 | Allow | 48 | 2 | 0 | No | No |
| 17684205 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | March 2022 | November 2022 | Allow | 8 | 1 | 0 | No | No |
| 17684229 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | March 2022 | December 2024 | Allow | 34 | 0 | 0 | No | No |
| 17684151 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | March 2022 | November 2022 | Allow | 9 | 1 | 0 | No | No |
| 17684290 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | March 2022 | November 2024 | Allow | 33 | 0 | 0 | No | No |
| 17684243 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | March 2022 | December 2022 | Allow | 9 | 1 | 0 | No | No |
| 17684272 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | March 2022 | November 2022 | Allow | 9 | 1 | 0 | No | No |
| 17684106 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | March 2022 | October 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17677814 | CD80 and CD86 Binding Protein Compositions and Uses Thereof | February 2022 | June 2025 | Allow | 40 | 1 | 0 | No | No |
| 17677283 | Anti-B7-H4 Antibodies and Immunoconjugates | February 2022 | December 2024 | Allow | 34 | 0 | 0 | No | No |
| 17677795 | CD80 and CD86 Binding Protein Compositions and Uses Thereof | February 2022 | September 2024 | Allow | 31 | 0 | 0 | No | No |
| 17668125 | DOSING REGIMEN OF AVELUMAB FOR THE TREATMENT OF CANCER | February 2022 | August 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17590918 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | February 2022 | February 2025 | Allow | 36 | 1 | 0 | No | No |
| 17582839 | ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF | January 2022 | August 2025 | Allow | 42 | 1 | 0 | No | No |
| 17571905 | ANTIBODIES WITH REDUCED IMMUNOGENICITY | January 2022 | January 2026 | Allow | 48 | 1 | 1 | No | No |
| 17622923 | SEMAPHORIN 3A ANTIBODIES AND USES THEREOF | December 2021 | August 2025 | Allow | 44 | 1 | 1 | No | No |
| 17554926 | Antigen Binding Proteins that Bind PD-1 | December 2021 | August 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17547528 | Anti-B7-H4 Antibodies and Immunoconjugates | December 2021 | June 2024 | Allow | 31 | 0 | 0 | No | No |
| 17529711 | ANTI-VISTA ANTIBODIES AND FRAGMENTS | November 2021 | August 2025 | Allow | 45 | 1 | 0 | No | No |
| 17523702 | TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY | November 2021 | August 2025 | Allow | 45 | 1 | 0 | No | No |
| 17482138 | Antibody Therapeutics that Bind CTLA4 | September 2021 | September 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17478587 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF | September 2021 | October 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17475766 | COMBINED CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD20 AND APPLICATION THEREOF | September 2021 | February 2022 | Allow | 5 | 1 | 0 | No | No |
| 17474702 | Combination Immunotherapy For The Treatment of Cancer | September 2021 | October 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17469359 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | September 2021 | December 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17469708 | PROTEIN M FUSION PROTEINS AND USES | September 2021 | June 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17412614 | ICOS BINDING PROTEINS | August 2021 | December 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17409118 | METHODS FOR UPREGULATING IMMUNE RESPONSES USING COMBINATIONS OF ANTI-RGMb AND ANTI-PD-1 AGENTS | August 2021 | July 2024 | Allow | 35 | 1 | 0 | No | No |
| 17407941 | METHODS OF REDUCING LIVER PD-1-EXPRESSING CD8+ T CELLS USING PD-1 FC FUSION PROTEINS THAT BIND FC RECEPTORS | August 2021 | April 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17402768 | VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER | August 2021 | April 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17399829 | HUMAN ANTIBODIES TO PD-L1 | August 2021 | March 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17444519 | USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS | August 2021 | October 2024 | Allow | 39 | 2 | 0 | No | No |
| 17428214 | CAR LIBRARY AND scFv MANUFACTURING METHOD | August 2021 | November 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17385636 | TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY | July 2021 | February 2025 | Allow | 42 | 1 | 0 | No | No |
| 17424484 | LEPTIN IMMUNOGENS, HYBRIDOMA CELLS, MONOCLONAL ANTIBODIES, POLYCLONAL ANTIBODIES AND USE THEREOF | July 2021 | February 2025 | Allow | 43 | 1 | 1 | No | No |
| 17373965 | BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR | July 2021 | March 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17372208 | TREATMENT OF RENAL CELL CARCINOMA | July 2021 | July 2024 | Allow | 36 | 2 | 1 | No | No |
| 17367133 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | July 2021 | February 2022 | Allow | 7 | 1 | 0 | No | No |
| 17367094 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | July 2021 | February 2022 | Allow | 8 | 1 | 0 | No | No |
| 17366878 | BISPECIFIC ANTIBODY | July 2021 | February 2024 | Allow | 31 | 1 | 1 | No | No |
| 17361393 | TREATMENT OF AUTOIMMUNE DISORDERS WITH CD154 ANTIBODIES | June 2021 | September 2023 | Allow | 27 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OUSPENSKI, ILIA I.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner OUSPENSKI, ILIA I works in Art Unit 1644 and has examined 1,379 patent applications in our dataset. With an allowance rate of 70.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 31 months.
Examiner OUSPENSKI, ILIA I's allowance rate of 70.6% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by OUSPENSKI, ILIA I receive 1.51 office actions before reaching final disposition. This places the examiner in the 27% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by OUSPENSKI, ILIA I is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +28.8% benefit to allowance rate for applications examined by OUSPENSKI, ILIA I. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 36.0% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 69.2% of cases where such amendments are filed. This entry rate is in the 91% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 96.8% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 93.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 40.5% are granted (fully or in part). This grant rate is in the 31% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 6.7% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.6% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.